CAS 500577-51-5

Cyclo(L-arginylglycyl-L-a-aspartyl-D-phenylalanyl-L-lysyl),mono(trifluoroacetate)

CAS: 500577-51-5

Formula: C₂₉H₄₂F₃N₉O₉

Purity: 98%

Color and Shape: Solid

Molecular weight: 717.6939

Ref: IN-DA01EB1F

2-((2S,5R,8S,11S)-8-(4-Aminobutyl)-5-Benzyl-11-(3-Guanidinopropyl)-3,6,9,12,15-Pentaoxo-1,4,7,10,13-Pentaazacyclopentadecan-2-Yl)Acetic Acid Trifluoroacetate

CAS: 500577-51-5

2-((2S,5R,8S,11S)-8-(4-Aminobutyl)-5-Benzyl-11-(3-Guanidinopropyl)-3,6,9,12,15-Pentaoxo-1,4,7,10,13-Pentaazacyclopentadecan-2-Yl)Acetic Acid Trifluoroacetate

Purity: 98%

Molecular weight: 717.69g/mol

Ref: 54-PC108413

Cyclo(-RGDfK) TFA

CAS: 500577-51-5

Cyclo(-RGDfK) TFA

Purity: ≥98%

Molecular weight: 717.69g/mol

Ref: 54-BUP01160

Cyclo(-RGDfK) TFA

CAS: 500577-51-5

Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).

Formula: C₂₉H₄₂F₃N₉O₉

Purity: 98.99% - 99.54%

Color and Shape: Solid

Molecular weight: 717.69

Ref: TM-T6812L

Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate

CAS: 500577-51-5

Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate is a cyclic peptide that has been shown to be an effective chemotherapeutic agent against bladder cancer. Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate binds to the integrin receptor on the tumor cell surface and blocks the formation of new blood vessels, which may lead to tumor growth inhibition. The hypoxic tumor environment is characterized by low oxygen levels, which causes the mitochondria in cells to produce more hydrogen peroxide. Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate has been shown to decrease the production of hydrogen peroxide in hypoxic tumors. This drug also inhibits angiogenesis and cellular proliferation. Cyclo(-Arg-Gly-Asp) trifluoroacetate has

Formula: C₂₇H₄₁N₉O₇•C₂HF₃O₂

Purity: Min. 98 Area-%

Color and Shape: White Off-White Powder

Molecular weight: 717.7 g/mol

Ref: 3D-FC110054